1.
Blood Rev
; 16(3): 167-74, 2002 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12163002
RESUMO
Multiple myeloma (MM) continues to evade cure by conventional therapies, increasing the urgency for new, biologically based treatments. Reviewed in this discussion are novel chemotherapies under clinical trial that capitalize upon greater comprehension of tumor pathophysiology. In targeting tumor biology, these therapies serve as a model of treatment with great potential for improving outcomes in patients with MM.